Program
APIM-containing Peptide ATX-101
Also written as “ATX-101”, “ATX101” and “ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)”.
Its studies are mostly in Pain, Postoperative · Ovarian Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 100 open or running | phase 3since Apr 22, 2014 | Jan 23, 2008 | none ahead |
| Allay Therapeutics | 20 open or running | phase 2since Feb 18, 2022 | Feb 18, 2022 | none ahead |
| Aurobac Therapeutics SAS | 10 open or running | phase 1since Jul 25, 2025 | Jul 25, 2025 | none ahead |
| THERAPIM PTY | 10 open or running | phase 2since Mar 4, 2021 | Mar 4, 2021 | none ahead |
Also a collaborator on its studies: Novotech (Australia) Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 23, 2008First study: phase 1 study in HealthyNew to AbbVieAbbVie · NCT00618709 · 24 enrolled · United States
- Feb 3, 2009Phase 1 study in Characteristics of Subcutaneous FatAbbVie · NCT00835952 · 14 enrolled · United States
- Mar 18, 20112 phase 1 studies in HealthyAbbVie · NCT01320761, NCT01319916
- Oct 17, 2011Phase 1 study in HealthyAbbVie · NCT01462786 · 5 enrolled · United States
- Jun 29, 2012Phase 1 study in HealthyAbbVie · NCT01632917 · 24 enrolled · United States
- Oct 11, 2012Phase 1 study in HealthyAbbVie · NCT01706679 · 218 enrolled · United States
- Apr 22, 2014Phase 3 study in Moderate to Severe Convexity of Submental FatAbbVie · NCT02123134 · 55 enrolled · United States
- Jun 6, 2014Phase 2 study in Submental FatAbbVie · NCT02159729 · 205 enrolled · United States, Australia, Canada and more
- Jun 12, 2014Phase 3 study in Submental FatAbbVie · NCT02163902 · 224 enrolled · United States, Canada
- Mar 4, 2021THERAPIM PTY’s first study: phase 2 study in Ovarian NeoplasmsNew to THERAPIM PTYTHERAPIM PTY · NCT04814875 · 16 enrolled · Australia
- Feb 18, 2022Allay Therapeutics’ first study: phase 2 study in Pain, PostoperativeNew to Allay TherapeuticsAllay Therapeutics · NCT05260008 · 112 enrolled · Australia, Canada, United Kingdom
- Jan 24, 2025Phase 2 study in Pain, PostoperativeAllay Therapeutics · NCT06799845 · 226 enrolled · United States
- Jul 25, 2025Aurobac Therapeutics SAS’ first study: phase 1 study in Healthy ParticipantsNew to Aurobac Therapeutics SASAurobac Therapeutics SAS · NCT07107802 · 24 enrolled · Portugal
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07107802Healthy Participants · Portugal | 1 | Completed | Aurobac Therapeutics SAS | Oct 24, 2025 | 24 |
| NCT06799845Pain, Postoperative · United States | 2 | Completed | Allay Therapeutics | Oct 3, 2025 | 226 |
| NCT05260008Pain, Postoperative · Australia, Canada, United Kingdom | 2 | Terminated | Allay Therapeutics | Jan 15, 2024 | 112 |
| NCT04814875Ovarian Neoplasms · Australia | 2 | Terminated | THERAPIM PTY | Nov 30, 2023 | 16 |
| NCT02163902Submental Fat · United States, Canada | 3 | Completed | AbbVie | Jan 2016 | 224 |
| NCT02159729Submental Fat · United States, Australia, Canada and more | 2 | Completed | AbbVie | Dec 2015 | 205 |
| NCT02123134Moderate to Severe Convexity of Submental Fat · United States | 3 | Completed | AbbVie | Aug 2015 | 55 |
| NCT01706679Healthy · United States | 1 | Completed | AbbVie | Feb 2013 | 218 |
| NCT01632917Healthy · United States | 1 | Completed | AbbVie | Jul 2012 | 24 |
| NCT01462786Healthy · United States | 1 | Completed | AbbVie | Nov 2011 | 5 |
| NCT01320761Healthy · United States | 1 | Completed | AbbVie | 24 | |
| NCT01319916Healthy · United States | 1 | Completed | AbbVie | Jan 2011 | 10 |
| NCT00835952Characteristics of Subcutaneous Fat · United States | 1 | Completed | AbbVie | Mar 2009 | 14 |
| NCT00618709Healthy · United States | 1 | Completed | AbbVie | Dec 2008 | 24 |
How it is read
Names in the registry
- “ATX-101”, 8 entries
- “ATX101”, 2 entries
- “ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)”, 1 entry
- “ATX-101 (1 mg/cm^2)”, 1 entry
- “ATX-101 (2 mg/cm^2)”, 1 entry
Conditions, from the studies’ own filings
- Pain, Postoperative, 2 studies
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.